Key result
DAPT pretreatment in NSTEMI shows substantial site-level variation, with a ~3.9-fold higher median.
Why the study?
What is the degree of hospital site-level variation and which patient-level factors are associated with DAPT pretreatment prior to angiography in patients presenting with NSTEMI?
Cohort (n=1,632)
Yes
What is the degree of hospital site-level variation and which patient-level factors are associated with DAPT pretreatment prior to angiography in patients presenting with NSTEMI?
Answers are grounded in this paper and cite their sources.
Despite guideline recommendations at the time, DAPT pretreatment in NSTEMI was used in only 22% of patients and showed nearly 4-fold variation across hospital sites independent of patient bleeding or CABG risk, highlighting that institutional protocols rather than individualized risk assessment drive practice.
BACKGROUND: Despite guideline recommendations, a significant number of patients with non-ST elevation myocardial infarction (NSTEMI) do not receive dual antiplatelet therapy (DAPT) before angiography "pretreatment." While there may be valid clinical reasons to not pretreat, such as concern for bleeding or multivessel disease warranting coronary artery bypass graft surgery, the degree of variability and factors associated with DAPT pretreatment are unknown. METHODS AND RESULTS: From the multicenter TRIUMPH registry, 1632 NSTEMI patients were not taking DAPT on admission and were included in the study cohort. Among the study patients, only 22% patients received DAPT pretreatment. A multivariable logistic regression model showed that race other than white or black (odds ratio [OR] 0.41, 95% CI 0.21-0.83), hemoglobin level (OR 1.18, 95% CI 1.08-1.29), patients' bleeding risk (assessed with NCDR CathPCI Bleeding Risk Score) (OR 0.85, 95% CI 0.74-0.99), and severe left ventricular dysfunction (OR 0.3, 95% CI 0.13-0.65) were the main predictors of pretreatment with DAPT, whereas likelihood of needing coronary artery bypass graft surgery (GRACE prediction model) was not (OR 1.09, 95% CI 0.88-1.35). Median ORs were calculated to assess variability of receiving DAPT pretreatment across sites after adjustment for patient characteristics. Receiving DAPT pretreatment varied substantially across sites (range 0-100%, mean OR 3.94, P<0.0001). CONCLUSIONS: While deviating from guideline-recommended DAPT pretreatment in patients with NSTEMI was associated with patient factors (eg, bleeding risk), marked variation was present across sites after accounting for patient-level characteristics. This suggests that site-level interventions are needed to improve concordance with current guidelines.
No takes yet. Share an insight, caveat, or question.
Shafiq et al. (2016) conducted a cohort in Non-ST-elevation myocardial infarction (NSTEMI) (n=1,632). Patient-level and site-level factors associated with DAPT pretreatment (aspirin plus clopidogrel or ticlopidine before coronary angiography) vs. No DAPT pretreatment before angiography was evaluated on Receipt of dual antiplatelet therapy (DAPT) pretreatment prior to coronary angiography and site-level variation (OR 3.94, 95% CI 2.04-6.09, p=<0.0001). DAPT pretreatment was administered to only 22% of NSTEMI patients and varied substantially across hospital sites.
Synapse has enriched 10 related papers. Consider them for comparative context: